One of the most important clinical problems in venous thrombotic disease is to determine whether a patient can safely cease oral anticoagulant therapy. Considering that an individual's venous thrombosis and bleeding risks do not decrease much over time, the decision on treatment duration has strong lifelong implications, as the cumulative risks will become high over a person's lifetime. 1 The current guidelines advise to classify all patients in two groups, with either high or low risk of recurrence. 2,3 This classification is based on one determinant (i.e., whether the index event was provoked by a transient risk factor or whether it was unprovoked). Roughly speaking, the high-risk group is advised to continue treatment indefinitely and the low risk group is advised to stop after 3 months. There are several problems with this approach: first, the definition of "(un)provoked" is unclear and varies between centers and over time 4 ; second, it disregards the strong individual differences between patients; and third, a validated tool to determine the bleeding risk is not included. This situation is unsatisfactory for both patients and doctors.
Worcester venous thromboembolism (VTE) study included patients with both a provoked and unprovoked first venous thrombosis, 10 whereas the other studies were all restricted to patients with unprovoked events. In the Multiple Environment and Genetic Assessment (MEGA) follow-up study, the results of the external validation of three prediction models (Vienna, HERDOO2, and DASH) showed lower C-statistics when we followed our own definition of unprovoked venous thrombosis than when we followed the definitions of the original studies. 11 This reinforces that the definition of "unprovoked venous thrombosis" is unclear and that the performance of the models will be poorer when a clinician uses his or her own definition of "unprovoked" venous thrombosis.
| IND IVIDUAL D IFFEREN CE S B E T WEEN PATIENTS
The problem with applying the current guidelines is that it denies all patients with provoked first events (approximately 50% of total) extended treatment. The incidence of recurrence is not negligible in this group (up to 10% in 2 years) 1 and varies greatly over individual patients, depending on their particular risk factors. In our MEGA follow-up study we found that the absolute risk of recurrence in patients with a first provoked event varied depending on the presence of other risk factors. 11 For instance, men with venous thrombosis provoked by something other than surgery and a high D-dimer level had an absolute recurrence risk of 6.0% (95% confidence interval
[CI], 3.9-9.2) per year; this risk was virtually similar to that in men who had unprovoked venous thrombosis and a high D-dimer level.
In contrast, women with unprovoked first venous thrombosis and a low D-dimer had an absolute risk of only 2.6% (95% CI, 1.5-4.4) per
year to develop recurrence.
| PRED IC TING THE RIS K OF MA JOR B LEED ING WHILE B EING ANTI COAG UL ATED
Currently, one prediction model has been specifically developed for major bleeding during extended anticoagulation for venous thrombosis (i.e., the SAMe-TT 2 R 2 score). 12 This score does not predict the long-term bleeding risk in anticoagulated venous thrombosis patients well with a C-statistic of 0.52. 12 Some information on bleeding risks resulting from long-term anticoagulation therapy can be inferred from studies in patients with atrial fibrillation. 13 This is not ideal because patients with atrial fibrillation are, in several respects, different from those with venous thrombosis.
In addition, the developed risk scores do not accurately predict major bleeding in patients with atrial fibrillation who require longterm anticoagulant treatment. 14 A model, developed in patients with venous thrombosis (i.e., the VTE-BLEED score), 14 performed well in a subsequent validation study. 15 However, the original study 14 limited follow-up to only 6 months of acute treatment, which information may not be very useful since all patients with venous thrombosis require at least 3-6 months of anticoagulant treatment. Although this issue was addressed in a validation study, where follow-up could now be 12 months, 15 final proof of efficacy in an outcome trial is needed before it may be recommended to be used in daily clinical practice.
| WHY S HOULD WE BOTHER ABOUT PREDIC TING RECURRENT VENOUS THROMBOS IS RIS K?
It could be argued that prediction of recurrent venous thrombo- the noninferiority of the reduced dose of DOAC to the full-dose treatment regimen, so any conclusion with respect to this issue is speculative.
These studies therefore provide no useful evidence but merely illustrate the importance of risk refinement, as patients with a moderately high recurrence risk and a low bleeding risk may benefit from this strategy of low dosing. However, patients with a high recurrence risk may truly need a standard dose DOAC, unless they have high bleeding risk, in which case they may need low dosing. Finally, those with low recurrence risk should not be exposed to prolonged treatment at all, not even to low-dose DOACs.
| WHAT THE FUTURE MI G HT B RING
In current practice, risk estimation of recurrent venous thrombosis and bleeding at an individual level is performed only crudely.
This implies that a large proportion of patients with a first venous thrombosis is either over-or undertreated with anticoagulants, for a prolonged period, leading to high lifetime risks of both recurrence and bleeding. We propose to individually classify patients with respect to thrombotic and bleeding risk and subsequently determine who will benefit from anticoagulant treatment and who will be unnecessarily exposed to its risks. To achieve this, further studies are needed in which the following issues should be considered:
First, one should not be too focused on results of the C-statistic only. For instance, the assumption that a model only works well if the C-statistic is high (e.g., higher than 0.7) is flawed because the C-statistic only describes how well models can rank order highrisk patients and low-risk patients, but is not a function of the actual predicted probabilities. 21 As an example, consider data from the MEGA follow-up study, in which the C-statistic for a model only including factor VIII was 0.60. 22 This means that the probability is 60% that a patient with recurrence has a higher factor VIII level than a patient who did not develop recurrence. This infor- which is a clinically relevant difference, and this knowledge is therefore more informative than the C-statistic. It is important to mention here that exposure variables for which the relative risk of a disease is ≤3 have little impact on the C-statistic. 23 When studying a disease that is not very prevalent, for example first venous thrombosis, a relative risk of 3 for a high level of a certain biomarker would shift the estimated 5-year risk from 0.5% to only 1.5%; a clinically unimportant difference. This is clearly different when the absolute risks are much higher as is the case for recurrent venous thrombosis. Then the same high biomarker level could alter the estimated 5-year risk of a recurrent venous thrombotic event from 10% to 30%, which could lead to different treatment recommendations. Thus, for risk prediction, the actual or absolute predicted risk, which is not captured by the C-statistic, is of primary clinical interest.
Second, one should develop a model that applies to all patients, and not only to patients with unprovoked venous thrombosis.
Although unprovoked venous thrombosis is clearly associated with a higher risk of recurrence than a provoked event, 1-3 the risk of recurrence in those with a provoked event is not negligible and varies greatly among patients, as discussed previously. As was shown in the MEGA follow-up study, within groups that are currently thought to have with a low recurrence risk (provoked first event, women), a high factor VIII level was still predictive for recurrent events. 22 This implies that a more refined risk estimation is possible at an individual level.
Third, biomarkers such as D-dimer and factor VIII levels improve prediction of a recurrent event. 1, [5] [6] [7] [8] 11, 22 However, discontinuation of anticoagulation treatment (both vitamin K agonists and DOACs)
is needed for reliable measurements. A period between discontinuation for blood sampling and restart of anticoagulation might confer an additional risk period of recurrence. All relevant information for assessing a patient's risk should therefore be determined during anticoagulant treatment. Genetics and clinical variables can be useful for this purpose. D-dimer levels or coagulation factor assays may be feasible, but under strict measurement conditions. 24, 25 Fourth, not only recurrence risk should be incorporated in a risk score but also the bleeding risk when extending anticoagulation. Predicting these risks in the elderly may be particularly useful because current predictive scores for recurrence have failed in elderly patients, 26 whereas elderly patients are at increased risk of bleeding while using anticoagulant treatment. 2 Finally, whatever prediction rule is developed, it needs external validation and successful application in practice as tested in appropriately designed clinical trials.
| CON CLUS ION
The predictive ability of the currently available models is limited and the current guidelines advise to estimate a patient's recurrence risk based only on whether or not the first event was provoked; however, the definition of provoked/unprovoked determines the prediction of the respective associated risks but varies strongly. Furthermore, risks of recurrence vary according to presence of well-described risk factors and a much more refined risk estimation is possible than the current binary stratification. Properly conducted controlled studies into development of new models are needed that take the following into account: (a) reporting of absolute risks next to C-statistic, (b) applicable to all patients, and (c) no discontinuation of anticoagulation necessary. This way, by determining individual risk profiles for both recurrent thrombosis and bleeding risk, personalized treatment is possible, by which occurrence of both conditions will be minimized.
